- Home
- BRKR vs CYTK Comparison
BRKR vs CYTK Comparison
Compare BRKR & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRKR
- CYTK
- Stock Information
- Founded
- BRKR 1960
- CYTK 1997
- Country
- BRKR United States
- CYTK United States
- Employees
- BRKR N/A
- CYTK N/A
- Industry
- BRKR Biotechnology: Laboratory Analytical Instruments
- CYTK Biotechnology: Pharmaceutical Preparations
- Sector
- BRKR Industrials
- CYTK Health Care
- Exchange
- BRKR Nasdaq
- CYTK Nasdaq
- Market Cap
- BRKR 5.3B
- CYTK 4.6B
- IPO Year
- BRKR 2000
- CYTK 2004
- Fundamental
- Price
- BRKR $47.34
- CYTK $65.25
- Analyst Decision
- BRKR Buy
- CYTK Strong Buy
- Analyst Count
- BRKR 10
- CYTK 15
- Target Price
- BRKR $45.67
- CYTK $77.87
- AVG Volume (30 Days)
- BRKR 2.9M
- CYTK 1.9M
- Earning Date
- BRKR 11-03-2025
- CYTK 11-05-2025
- Dividend Yield
- BRKR 0.46%
- CYTK N/A
- EPS Growth
- BRKR N/A
- CYTK N/A
- EPS
- BRKR N/A
- CYTK N/A
- Revenue
- BRKR $3,438,900,000.00
- CYTK $87,211,000.00
- Revenue This Year
- BRKR $4.27
- CYTK $363.61
- Revenue Next Year
- BRKR $1.34
- CYTK $64.33
- P/E Ratio
- BRKR N/A
- CYTK N/A
- Revenue Growth
- BRKR 6.10
- CYTK 2609.26
- 52 Week Low
- BRKR $28.53
- CYTK $29.31
- 52 Week High
- BRKR $64.64
- CYTK $67.98
- Technical
- Relative Strength Index (RSI)
- BRKR 78.35
- CYTK 57.35
- Support Level
- BRKR $40.64
- CYTK $59.85
- Resistance Level
- BRKR $43.37
- CYTK $67.98
- Average True Range (ATR)
- BRKR 1.76
- CYTK 2.83
- MACD
- BRKR 0.39
- CYTK -0.28
- Stochastic Oscillator
- BRKR 97.99
- CYTK 72.16
About BRKR Bruker Corporation
Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, applied markets, pharmaceutical, and biotechnology industries. The company operates in segments, namely, Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Supercon Technologies (BEST). The company generates maximum revenue from the BSI CALID segment. Geographically, it derives the maximum of its revenue from United States.
About CYTK Cytokinetics Incorporated
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.